Evidence map›Paper›PMID 38712343›Full record

ReviewFrontiers in molecular biosciences2024

The role of zyxin in signal transduction and its relationship with diseases.

Zelan Wu, Daiqin Wu, Qin Zhong, Xue Zou, Zhongjing Liu, Hehua Long, Jing Wei, Xia Li, Fangjie Dai

Abstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zelan Wu *Department of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Daiqin Wu *Department of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Qin ZhongClinical Research Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xue ZouClinical Research Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Zhongjing LiuClinical Research Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Hehua LongSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang, China.
Jing WeiDepartment of Endocrinology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xia LiGuizhou Precision Medicine Institute, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Fangjie DaiDepartment of Cardiovascular Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review highlighted the pivotal role of zyxin, an essential cell focal adhesions protein, in cellular biology and various diseases. Zyxin can orchestrate the restructuring and dynamic alterations of the cellular cytoskeleton, which is involved in cell proliferation, adhesion, motility, and gene transcription. Aberrant zyxin expression is closely correlated with tumor cell activity and cardiac function in both tumorigenesis and cardiovascular diseases. Moreover, in fibrotic and inflammatory conditions, zyxin can modulate cellular functions and inflammatory responses. Therefore, a comprehensive understanding of zyxin is crucial for deciphering signal transduction networks and disease pathogenesis. Investigating its role in diseases holds promise for novel avenues in early diagnosis and therapeutic strategies. Nevertheless, targeting zyxin as a therapeutic focal point presents challenges in terms of specificity, safety, drug delivery, and resistance. Nonetheless, in-depth studies on zyxin and the application of precision medicine could offer new possibilities for personalized treatment modalities.

Indexed as

cardiovascular diseasesinflammatory responsessignal transduction networkstumorigenesiszyxin

Identifiers

PMID38712343
PMCPMC11070705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.